Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04269213 · ClinicalTrials.gov registry record · Phase 2
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
A Phase 2 study of Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia, sponsored by Roswell Park Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 4
- Study locations
NCT04269213: Active Phase 2 study of Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia, sponsored by Roswell Park Cancer Institute.
NCT04269213 is a Phase 2 study of Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia that is active but no longer recruiting, run by Roswell Park Cancer Institute. The registered enrollment target is 21 participants, below the 63-participant average among 21 other Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome trials with a reported enrollment target (67% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04269213, a Phase 2 study of Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia, is active but no longer recruiting, sponsored by Roswell Park Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Primary Outcome
Defined by the International Working Group Criteria. Will be summarized using frequencies and relative frequencies.
Conditions Studied
Interventions
- DRUG Liposome-encapsulated Daunorubicin-Cytarabine
Study Locations (4)
New York
- Roswell Park Cancer Institute - Buffalo
- SUNY Upstate Medical Center - Syracuse
Nebraska
- University of Nebraska Medical Center - Omaha
Pennsylvania
- Allegheny Health Network Cancer Institute - West Penn Hospital - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2021-07-29 |
| Est. Completion | 2027-01-29 |
| Phase | Phase 2 |
What the registry record for NCT04269213 still lists
NCT04269213 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 63-participant average among 21 other Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome trials with a reported enrollment target (67% lower).
The record links to 4 conditions, with Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Liposome-encapsulated Daunorubicin-Cytarabine is the first listed.
NCT04269213 reports a single indexed study location in New York, Nebraska, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04269213 about?
NCT04269213 is a clinical study titled "CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old". This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, eit...
What is the current status of trial NCT04269213?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2021-07-29. Estimated completion is 2027-01-29.
What conditions does trial NCT04269213 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes.
What interventions are being tested in trial NCT04269213?
The interventions under investigation include: Liposome-encapsulated Daunorubicin-Cytarabine (DRUG).
Who is sponsoring clinical trial NCT04269213?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04269213 being conducted?
This trial has 4 study locations across Nebraska, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04269213's enrollment target sits among peer trials
21 20th of 21 higher than 2 of 21 other Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue
ACTIVE NOT RECRUITING · Phase 2
-
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI